Aewell Technology’s non-GAAP net profit surged by 47.91%. Behind this high growth, what challenges remain?

On the last trading day of February, Aewell Technology (688067) released its 2025 annual performance快报, and a series of impressive figures attracted widespread market attention. Revenue reached RMB 230 million, up 13.14% year-on-year; net profit attributable to shareholders amounted to RMB 28.94 million, up 26.72% year-on-year. At first glance, this performance is already commendable amid the current market environment. Yet what truly stands out is another figure: non-GAAP net profit totaled RMB 23.07 million, surging 47.91% year-on-year. What does this mean? Simply put, the company’s ability to generate profits from its core business is improving at a pace far exceeding revenue growth. Amid slowing economic growth and with many enterprises still focused on cost-cutting for survival, what enables Aewell Technology to achieve ‘quality improvement and efficiency enhancement’? 01 The ‘Two Sides’ Behind the Impressive Figures According to the performance快报, Aewell Technology’s total operating revenue for 2025 was RMB 230 million, up 13.14% year-on-year; net profit attributable to shareholders rose 26.72% year-on-year to RMB 28.94 million; and non-GAAP net profit—the clearest indicator of core business performance—reached RMB 23.07 million, soaring 47.91% year-on-year. Superficially, this is a textbook case of ‘revenue growth accompanied by even stronger profit growth’. A 13% revenue increase translated into nearly 48% growth in non-GAAP profit—indicating a qualitative improvement in earnings quality. Yet upon closer examination of the announcement’s wording, several noteworthy details emerge. First, non-recurring gains shrank. While net profit attributable to shareholders grew 26.72%, non-GAAP net profit jumped 47.91%—the gap reflecting one-time gains excluded from the latter. In other words, if non-recurring gains had not declined year-on-year, would the financial results have looked even better—or is the company deliberately reducing its reliance on non-core income? Second, precise expense management ‘delivered results’. The announcement states: ‘The company’s expense control system, launched in November 2024, enabled precise expense management; during the reporting period, SG&A expenses grew at a slower rate than revenue.’ Could a newly implemented expense control system really yield such immediate, dramatic effects? Is this evidence of genuine managerial excellence—or were prior expenses inflated to begin with? 02 The Growth Engine: Who’s Carrying the Load? Beyond the numbers, what truly drives Aewell Technology’s growth? The announcement offers a key insight: ‘During the reporting period, sales of the company’s vaginal secretion analyzers and their accompanying reagents and consumables—as well as the hematology analysis流水 line launched in 2024—performed strongly, posting substantial year-on-year growth.’ This sentence carries significant implications: First, the ‘cash cow’ continues to deliver. Vaginal secretion analyzers and their associated reagents and consumables constitute Aewell Technology’s traditional strength. What defines reagent/consumable businesses? One-time instrument installation followed by recurring consumption. Once instruments are deployed, subsequent reagent sales generate steady, predictable cash flow. Growth in this segment signals strengthening customer retention and stickiness among existing clients. Second, the ‘newcomers’ are already stepping up. The hematology analysis流水 line, launched only in 2024, achieved ‘substantial year-on-year growth’ in 2025.

Net profit growth exceeded 16% in the third-quarter report; what’s behind Aewell Technology’s 212% surge in operating cash flow?

On a quarterly basis, Aewell Technology posted Q3 revenue of RMB 61.38 million, up 9.76% year-on-year; net profit attributable to shareholders reached RMB 15.18 million, up 12.22% year-on-year. Excluding non-recurring items such as government subsidies and investment income, non-GAAP net profit stood at RMB 13.86 million, up 16.35% year-on-year—demonstrating continued improvement in core business profitability. Yet another figure warrants attention: investment income totaled RMB 4.09 million, accounting for approximately 14% of net profit. Investors must ask: how much of the company’s earnings growth stems from ‘core business excellence’, and how much from ‘prudent financial management’? During the reporting period, basic EPS was RMB 0.43 per share, up 16.22% year-on-year; weighted average ROE reached 5.76%, an increase of 0.72 percentage points year-on-year—indicating steadily improving returns to shareholders. 02 Operating Cash Flow Soars 212%—Even More Impressive Than Net Profit A standout highlight of this quarterly report is operating cash flow: RMB 28.49 million for the first three quarters, up a staggering 212.67% year-on-year. Why does this number matter? Because while profits can be adjusted, cash flow is hard to ‘cosmeticize’. Aewell Technology attributes this surge to ‘increased sales volume, strengthened credit management for customers, and intensified collection of receivables’. In plain terms: not only were goods sold—but cash was actually collected. Compared with the 16.35% growth in net profit, the 212% surge in cash flow is truly remarkable. This reflects a substantive improvement in earnings quality and a significantly enhanced capacity for ‘self-sustaining cash generation’. 03 Sustained R&D Investment and Optimized Asset Structure As a STAR Market-listed company, R&D investment remains a focal point for investors. Despite revenue growth, Aewell Technology has not relaxed its R&D commitment. Total R&D investment for the first three quarters amounted to RMB 17.69 million, up 7.28% year-on-year; R&D expenses accounted for 10.35% of revenue—maintaining a consistently high intensity, laying the groundwork for long-term product iteration and technological moat building. However, R&D expenses as a share of revenue—10.35%—declined slightly by 0.42 percentage points year-on-year.

Avient Corp (AVNT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Jun 17, 2026

Analysts maintain a consensus "Buy" rating for Avient Corp (AVNT), projecting next quarter revenue of $894.27 million and EPS of $0.89. The company ranks 6th in the Chemicals industry with an average price target of $42.00.

TradingKey

2026-04-03

Avient Launches Hiformer Slip + Antistatic for BOPP Films

2026-04-15

Avient (AVNT) Proxy Filing Summary

2026-04-28

Avient Launches Hiformer Slip + Antistatic for BOPP Films in Latin America

2026-06-12

Avient Corp Shares Rise 3.4% as GF Value Suggests Undervaluation

2026-06-17

Avient Corp (AVNT) Earnings Forecast: Future EPS & Revenue Growth Estimates